For pharmaceutical companies, Mercy Halo™ offers an opportunity to accelerate clinical development programs through exploratory sample analysis for key tumor-derived biomarkers. Future offerings will include patient screening for clinical trial enrollment and companion diagnostic development to support new drug commercialization.
Extracellular Vesicles in Early Cancer Detection
Robust peer-reviewed literature demonstrates the potential of EVs in early cancer detection.
The Mercy Halo™ Test in Partnership
Mercy BioAnalytics works with companies who want to increase the chances of a drug’s success in clinical trials. Mercy Halo™ helps identify patients whose cancer has the right molecular profile for their clinical program, monitor their response to investigational drugs or combinations of drugs, and perform retrospective analyses on previously archived plasma or serum samples.
I can do things you cannot, you can do things I cannot;
together we can do great things.
Join Mercy BioAnalytics on our lifesaving mission to detect cancer early when it is most curable.
Please use the form below for collaboration inquiries